Protein / target
Succinate-semialdehyde dehydrogenase, mitochondrial
Protein at a glance
Biological role
Succinate-semialdehyde dehydrogenase (NAD+) activity
Primary system
Nervous system
Strongest disease association
succinic semialdehyde dehydrogenase deficiency
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
3 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)
Subcellular location
Domains and Gene Ontology detail (8)Hide
Gene Ontology
- Cmitochondrial matrix
- Cmitochondrion
- Fidentical protein binding
- Fsuccinate-semialdehyde dehydrogenase (NAD+) activity
- Pcentral nervous system development
- Pgamma-aminobutyric acid catabolic process
- Pglutamate metabolic process
- Psuccinate metabolic process
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Metabolic enzyme activity
- ·succinate-semialdehyde dehydrogenase (NAD+) activity
- ·glutamate metabolic process
- ·succinate metabolic process
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Succinate semialdehyde dehydrogenase inhibitor
Appears in clinical studies involving Generalized non-motor (absence) seizure, complex partial epilepsy, epilepsy, Seizure
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,172 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 3 total
Generalized non-motor (absence) seizure · complex partial epilepsy · epilepsy
Generalized non-motor (absence) seizure · bipolar disorder · epilepsy
epilepsy · neuropathic pain · alcohol dependence
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Supplemental approval
Supplemental approval: VALPROIC ACID (ANDA073229)
- New publicationA phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
- New publicationCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
- Label change
Label change: VALPROIC ACID (ANDA073229)
- Label change
Label change: VALPROIC ACID (ANDA073229)
- Label change
Label change: VALPROIC ACID (ANDA073229)
- Supplemental approval
Supplemental approval: VALPROIC ACID (ANDA073229)
- Label change
Label change: VALPROIC ACID (ANDA073229)
- Supplemental approval
Supplemental approval: VALPROIC ACID (ANDA073229)
- Supplemental approval
Supplemental approval: VALPROIC ACID (ANDA073229)
- Supplemental approval
Supplemental approval: VALPROIC ACID (ANDA073229)
- Supplemental approval
Supplemental approval: VALPROIC ACID (ANDA073229)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.